Following a remission induction phase, 41 patients in remission at week 12 were randomized to receive either placebo infusions or monthly abatacept. as key inflammatory cells in both active and chronic vascular inflammatory lesions. Therapeutic agents, including abatacept and ustekinumab, which can impede both vasculitogenic cell lines are of particular interest. Inhibition of signalling pathways, … Continue reading Following a remission induction phase, 41 patients in remission at week 12 were randomized to receive either placebo infusions or monthly abatacept